←Back to Expert Scholars
Translational Medicine / 转化医学Nivolumab MSI-H CRC, CheckMate 142
Michael J. Overman
MD
🏢MD Anderson Cancer Center🌐USA
Professor of GI Medical Oncology
85
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Michael Overman led CheckMate-142 demonstrating nivolumab monotherapy and nivolumab+ipilimumab efficacy in MSI-H metastatic colorectal cancer. His work established dual checkpoint inhibition as a standard-of-care option for dMMR metastatic CRC.
Share:
🧪Research Fields 研究领域
CheckMate-142
nivolumab MSI-H
nivolumab ipilimumab dMMR
metastatic colorectal immunotherapy
MSI CRC
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Michael J. Overman 的研究动态
Follow Michael J. Overman's research updates
留下邮箱，当我们发布与 Michael J. Overman（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment